You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
Researchers argued that the field is ready for an expansion of adjuvant therapy trials informed by non-invasive, molecular measures of minimal residual disease.
Using data for more than half a million individuals, researchers identified 449 refractive area-related loci, including 336 sites not linked to the eye condition in the past.
The Observer reports that there have been calls for a University of College London geneticists to resign due to research fraud coming out of his lab.
A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.
These alterations, which can include hypermethylation of the H19 locus, can crop up during kidney development.
In PLOS this week: genetic adaptation in chimpanzees, transcriptional features of renal cell carcinoma, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
The number of technologies to be assessed is vast, and ranges from liquid biopsies and molecular imaging to immunohistochemistry and RNA-seq.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.